RG2634, a novel bispecific antibody targeting GPRC5D, for the treatment of RRMM

GRPC5D, a G protein-coupled receptor, is a key therapeutic target in multiple myeloma (MM) as it is highly expressed on...

Dara-KRd and tandem ASCT for patients with high-risk NDMM: Results of the IFM-2018-04 trial

In the IFM-2018-04 trial, the quadruplet of dara-KRd with tandem transplant was assessed in patients with...

Efficacy of OriCAR-017, a GPRC5D-directed CAR T-cell therapy, in patients with R/R MM: Findings from the POLARIS study

OriCAR-017 is a second-generation, autologous, GPRC5D-directed CAR T-cell...

Efficacy and safety of ARI0002h, an academic BCMA-directed CAR T-cell therapy for RRMM

ARI0002h is a 4-1BB based CAR T-cell product containing a humanized single chain variable BCMA-targeting...

Classification and treatment of frail and ultra frail patients with multiple myeloma: challenges and future perspectives

Here, we review an oral presentation, given on May 15, 2022, at the 8th World...

What are the initial results of ADC-based combinations?

The Multiple Myeloma Hub was pleased to speak to Rajshekhar Chakraborty, Herbert Irving Comprehensive Cancer Center, New York, US. We asked,...

COMy 22

Catch up with our live twitter coverage from the 8th Controversies in Multiple Myeloma (COMy) Congress, 2022.

The PROMISE study: What have we learnt about MGUS prevalence and clinical implications?

During the 8th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub was pleased...

Weighing up PFS and OS in the DETERMINATION trial: Re-evaluating the role of transplant in myeloma

The role of autologous hematopoietic stem cell transplantation (auto‑HSCT) is evolving, and the most...

The role of consolidation after autologous stem cell transplantation

During a meeting of the Multiple Myeloma Hub Steering Committee on April 26, 2022, Morie Gertz chaired a recorded discussion that...

Recommendations for transplantation in MM from the American Society for Transplantation and Cellular Therapy

The American Society of Transplantation and Cellular Therapy’s (ASTCT) Committee on...

What are the current and future strategies for maintenance therapy after autologous transplant?

During the 8th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub was...

EHA2022 abstracts: What's hot in multiple myeloma?

To help navigate the exciting content being presented at the EHA2022 Congress, the Multiple Myeloma Hub Steering Committee members have provided...

How do CAR T-cell recipients respond to COVID-19 vaccination?

During the 4th European CAR T-Cell Meeting, the Multiple Myeloma Hub was pleased to speak to Arnon Nagler, Sheba Medical Center, Tel Aviv,...

EMN recommendations for COVID-19 vaccination in patients with MM

Multiple myeloma (MM) and other monoclonal gammopathies can increase patient susceptibility to infection, either as a direct result of...

Humoral and cellular responses in patients with lymphoid malignancies receiving SARS-Cov-2 vaccination

Factors that influence the efficacy of Severe Acute Respiratory Syndrome Coronavirus-2...